Deutsche Bank analyst Glen Santangelo lowered his price target for McKesson to $160 citing "lingering fundamental concerns and upcoming contract renewals." The analyst, however, views the set-up for Q1 earnings, to be reported on July 26, as reasonable with consensus expecting earnings per share of $2.86, near the bottom of the company's guidance. Longer term, investors have become increasingly concerned that over the next two years McKesson will face certain customer renewals, which is presenting a lingering concern for the shares, Santangelo writes. The analyst keeps a Buy rating on McKesson.

Evercore ISI says that while neither OptumRx nor Cardinal Health (CAH) would confirm the winner of the contract, McKesson (MCK) confirmed it had won the contract beginning in July. Cardinal this morning announced that its pharmaceutical distribution contracts with OptumRx, which represented 16% of fiscal 2023 revenue, is expiring at end of June and will not be renewed. Evercore estimates the win would represent a 50c-65c earnings per share benefit to McKesson on a full-year basis or likely half of that given the contract does not start until July. The firm does not see Cardinal's announcement as "heralding a broadly more competitive period for the distributors, but rather a one-off contract shift given what was likely an off-market contract."